To include your compound in the COVID-19 Resource Center, submit it here.

The 2-day difference

Eisai Co. Ltd. and SuperGen Inc. aren’t expressing concern that Dacogen decitabine missed the primary endpoint of survival benefit in a European Phase III trial to treat myelodysplastic syndromes, as the partners maintain the trial used an outdated protocol. Although it’s unclear whether the negative outcome will affect a planned regulatory resubmission in Europe, the companies expect no changes in prescribing habits in the U.S., where the drug is already

Read the full 705 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE